Abstract
Findings
The FOXP3 gene plays a key role in regulating the immune response and its expression occurs under tight epigenetic control [1] . Notably, DNA demethylation of the 'Treg-specific-demethylated-region' (TSDR), located on the 2nd conserved non-coding sequence of FOXP3 (CNS2), is a sine qua non modification found in thymicderived T regulatory cells (tTregs-formerly known as nTregs) [2] . TSDR demethylation results in stable and high FOXP3 expression and suppressive function in tTregs. Using a modified RT-PCR approach, the amount of TSDR hypomethylation can be precisely measured from whole DNA providing a highly accurate quantitative biomarker to identify tTregs within whole blood, PBMCs or tissue samples [3] .
This said, epigenetic studies using pyrosequencing have also associated other loci on the FOXP3 gene, such as its promoter region, with various immune-related disease Open Access *Correspondence: philippe.begin@umontreal.ca † Philippe Bégin and Janika Schulze contributed equally to the manuscript # Rosa Baccheta and Kari C. Nadeau: Co-senior authors 4 Division of Allergy, Department of Pediatrics, CHU Sainte-Justine, Montreal, Canada Full list of author information is available at the end of the article states such as asthma [4] , food allergy [5] , auto-immunity [6, 7] and cancer [8] . Furthermore, the FOXP3+ T cell compartment comprises other cell subsets with methylated TSDR which have variable suppressive function [9] and FOXP3 can be transiently expressed by any nonsuppressive T conventional (Tconv) cells upon activation [10] . In mice, knocking-out the CNS1 results in a loss of peripheral tolerance with allergy and maternal-fetal conflict despite functional tTregs showing the importance of other control regions on FOXP3 and of non-tTreg FOXP3+ subsets to regulate the immune response [11] . We hypothesized that FOXP3+ subset-specific DNA methylation sites could be identified outside of the TSDR and used additively to design a more comprehensive, high-throughput assay to characterize the FOXP3+ T cell population in clinical samples. Characterizing the FOXP3+ T cell populations could have a high impact in monitoring and treating many diseases, including those diseases with autoimmunity, cancer, and allergy.
Given their potential clinical relevance and lack of available markers, we performed studies using induced Tregs (iTreg) as a target cell population to identify candidate hypomethylated CpG sites. iTregs are typically generated in vitro from naïve T cells with TCR-mediated stimulation in the presence of tumor growth factor (TGF)-β and interleukin (IL)-2. The expression of FOXP3 from the resulting iTreg population is very high but these cells remain fully methylated at the TSDR [1] . In humans, their suppressive function is not reliable although the addition of retinoic acid to the induction protocol has been reported to increase the stability of FOXP3 expression and of the suppressive function [12, 13] .
Briefly, naïve T cells were cell-sorted (BD FACSAria II ® ) from healthy control peripheral blood on consented adult blood bank donors as CD4+CD45RA+CD62L+CD25− and put in culture in AIM V medium (Life Technologies ® ) with 100 U/mL IL-2 (BD Pharmingen ® ), 10 ng/ mL TGF-β1 (R&D Systems ® ), and/or 100 nM ATRA (Sigma-Aldrich ® ) and anti-CD3/CD28 mAbs Dynabeads (Life Technologies ® ) at a bead:cell ratio of 1:20 (Fig. 1a) . Beads were removed with magnet at day 4 and cells were washed and re-plated with fresh medium with IL-2 at 100 UI/L. Cells were fixed at day 7 and sorted based on their intracellular expression of FOXP3 ( Fig. 1b-d) . DNA was extracted and bisulfite treated for pyrosequencing of the FOXP3 promoter and three conserved noncoding sequences regions (Fig. 1e) .
Interestingly, three CpG sites at the promoter regions (at positions −126, −77 and −56 from transcription start site) showed clear demethylation pattern associated with high FOXP3 expression after activation in presence of TGFβ (Fig. 1e ). There were no changes in demethylation of TSDR or other CNS regions. Addition of retinoic acid to TGFβ did not impact the demethylation of any CpG sites in the FOXP3 locus compared to TGFβ alone. The three CpG sites in the promoter region were selected as primary targets to design primers and probes to quantify the methylation of this 'inducible-promoter-demethylated-region' (IPDR) using the same method established for the TSDR (Fig. 1f ) [3, 14] .
The specificity and sensitivity of the assay was first confirmed by using methylated and demethylated synthetic plasmid sequences (Fig. 1g, h ) and then validated in cell populations with high methylation of the IPDR, as tested by pyrosequencing (i.e. granulocytes, monocytes, B cells and NK cells). To validate its quantitative value in samples, the IPDR assay was performed on whole T cells from an iTreg induction culture at baseline and day 7. A low percentage of naïve T cells showed IPDR demethylation at baseline. At day 7, in the presence of TGF-β, the fraction of IPDR demethylation was increased and the increment was correlated with the increased frequency of cells expressing high levels of FOXP3 protein (Fig. 2a) .
To investigate the distribution of IPDR demethylation in FOXP3+ T cell subsets we applied the assay to fresh peripheral T cell populations based on CD25 and CD45RA expression according to previously described classification [1] . Both naïve and memory tTreg cells (Fig. 2a) were found to be fully demethylated at both the IPDR and TSDR. Interestingly, both CD25− and CD25 lo conventional memory CD4+ T cells displayed a high fraction of IPDR demethylated cells (Fig. 2b) . Thus, while TSDR demethylation is required for sustained high expression of FOXP3 in tTregs, IPDR demethylation is associated with a wide range of (possibly transient) FOXP3 protein expression in antigen-experienced (See figure on next page.) Fig. 1 FOXP3 promoter RT-PCR assay design. Naïve T cells (CD4+CD45RA+CD62L+CD25−) were sorted from CD4 enriched buffy coats (a, red gate) and put in culture with IL-2 and CD3/CD28 stimulation in medium alone (b), in the presence of TGF-β (c) or both TGF-β and retinoic acid (d). At day 7, cells were sorted based on FOXP3 expression. FOXP3 high (green gates) and FOXP3 low samples (red gates), as well as baseline naïve tTreg controls (a, green gate) were pyrosequenced at the promoter and three conserved non-coding sequence regions of the FOXP3 gene (e). Promoter CpG sites at positions −126, −77 and −56 from transcription start site showed the greatest differential methylation in FOXP3 high TGF-induced T cells (iTregs) (indicated with arrows). These sites were selected to design primers and RT-PCR probes specific for their methylation status (f). Specificity of methylated and unmethylated RT-PCR primers and probes was validated using unmethylated (g) and methylated (h) plasmid standards dilutions at 31,250, 6250, 1250, 250 and 50 copy numbers per reaction T cells, ranging from negative to low protein expression in memory T cells, to high expression in iTregs. The high expression of FOXP3 protein in iTreg could be due to the additional effect of epigenetic modifications such as histone modifications, as suggested in mice [15] . Inversely, in non-activated CD25 −/lo memory T cells, the FOXP3 protein could be down-regulated at the post-translational level by STUB1-mediated ubiquitination and proteasomal degradation of the protein, which is induced by proinflammatory stimuli (IL-1, IL-6, LPS) [16] .
Such an ability to express and modulate low levels of FOXP3 with IPDR demethylation could be important for the homeostatic control of the antigen-experienced T cell population. Knocking down FOXP3 in non-regulatory T cells with siRNA demonstrated FOXP3 expression is critical for limiting cellular proliferation and cytokine production (intrinsic regulation) [10] .
This said, the variable demethylation of the IPDR in T cell subsets means that it cannot be used to quantify subsets from unfractioned blood like the TSDR assay. Controlling for CD45 expression in CD3 positive T cells may help improve test interpretation on mixed population sample but it is insufficient to account for all the inter-individual variability (data not shown) which may also stem demethylation of IPDR in effector (<30 %), naïve T cells (<20 %) which despite being low does contribute to the whole amount of demethylated DNA. This raises questions with regards to previous associations of FOXP3 promoter demethylation with immune disease states which were based on unfractioned blood analyses, which may need to be revisited by measuring IPDR demethylation in sorted specific T cell subsets. Further in depth analyses of IPDR demethylation in T cell subsets in large cohorts will also be needed to provide reference values for such analyses. Better characterization of IPDR demethylation in various subsets may eventually provide surface markers that will allow its interpretation in unfractioned samples.
In summary, we have identified an inducible promoter demethylated region (IPDR) of FOXP3 and designed a quantitative assay to accurately measure its methylation which is available for testing in clinical samples. Since IPDR demethylation in absence of TSDR demethylation is a feature of both iTregs and memory T cells, its use will minimally require taking in account the fraction of cell subsets in a given mixed sample, or ideally, pre-sorting of cell subsets prior to analysis. This approach could have diagnostic and prognostic value in patients with immune or auto-inflammatory diseases.
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